Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Disease‐specific quality of life · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted2 studies · 265 participantsModerate
Findings
What do systematic reviews say?
256 questions · 278 findings · 34 reviews · ENT
No studies found 86 · 30.9%GRADE not reported 1 · 0.4%Very low 88 · 31.7%Low 66 · 23.7%Moderate 35 · 12.6%High 2 · 0.7%
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Disease severity, as measured by validated, patient‐reported symptom score · patients with chronic rhinosinusitis with nasal polyps
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Serious adverse events · patients with chronic rhinosinusitis with nasal polyps
It is very uncertain whether anti‐IgE mAb (omalizumab) changes serious adverse events compared with placebo (on top of topical steroids) (very low certainty).
1 finding from 1 review
- RR 0.32 [0.05, 2]5 studies · 329 participantsVery low
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted3 studies · 784 participantsModerate
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
- RR 5.6 [1.99, 15.76]2 studies · 265 participantsLow
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Extent of disease ‐ endoscopic score · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted4 studies · 312 participantsLow
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Extent of disease ‐ CT scan (lower score = better) · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted2 studies · 47 participantsVery low
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Generic quality of life measures · patients with chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted2 studies · 38 participantsVery low
Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)
Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps
Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
- RR 0.71 [0.29, 1.73]5 studies · 329 participantsLow
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
- RR 0.47 [0.29, 0.76]3 studies · 782 participantsLow
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).
1 finding from 1 review
- RR 0.17 [0.05, 0.52]2 studies · 725 participantsModerate
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted3 studies · 784 participantsModerate
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted3 studies · 784 participantsHigh
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted3 studies · 766 participantsModerate
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).
1 finding from 1 review
- RR 0.95 [0.72, 1.25]3 studies · 783 participantsLow
Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)
Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps
1 finding from 1 review
- no estimate extracted1 study · 105 participantsLow
Topical antibiotics vs placebo/no treatment
Resolution of ear discharge ‐ measured at 1 to 2 weeks · patients with mucopurulent otorrhoea
It is very uncertain whether topical antibiotics changes resolution of ear discharge ‐ measured at 1 to 2 weeks compared with placebo/no treatment (very low certainty).
1 finding from 1 review
- RR 6.74 [1.82, 24.99]1 study · 35 participantsVery low
Topical antibiotics vs placebo/no treatment
Resolution of ear discharge ‐ measured after 4 weeks · patients with mucopurulent otorrhoea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical antibiotics vs placebo/no treatment
Health‐related quality of life · patients with mucopurulent otorrhoea
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Topical antibiotics vs placebo/no treatment
Ear pain (otalgia) or discomfort or local irritation · patients with mucopurulent otorrhoea
1 finding from 1 review
- no estimate extracted1 study · 35 participantsVery low